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despite aggressive therapy of rheumatoid
arthritis?’
Pierre MiossecDuring the last 20 years, obvious progress has been
made in the care of patients with rheumatoid arthritis
(RA). This results from the combination of better diag-
nosis, earlier use of classic drugs, and the introduction
of new targeted therapies. Despite these positive results,
RA remains a chronic disease and induction of remis-
sion is still rarely obtained [1]. It is as if RA were a series
of lost battles. More recently, although RA care im-
proved, chronic inflammation was shown to have an ef-
fect on mortality, specifically from cardiovascular events.
The goal of this series of short articles on RA chron-
icity is to give readers of Arthritis Research & Therapy
the views of leading experts in the field. This combines
lessons coming from daily clinical observations to a bet-
ter understanding of basic molecular changes in mesen-
chymal cells.A question of definition
RA is a heterogeneous disease, as reflected by the vari-
ous degrees of joint destruction and disability between
patients. The complexity of such heterogeneity has been
increasing over time with more markers, from autoanti-
bodies and human leukocyte antigen (HLA) subtypes to
extensive genome-wide polymorphisms and serological
markers. Use of these markers has been helpful at a stat-
istical level to compare populations but much less so to
predict severity for a given patient.
If it is not possible to have a simple definition of a dis-
ease, we could mix different entities under the same defin-
ition. This is strongly stated by Gary Firestein, who
proposes that we now need to consider RA a syndrome in
order to include the different etiologies, clinical presenta-
tion and severity, and response rates to treatment [2].Correspondence: miossec@univ-lyon1.fr
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2014If RA is now a syndrome, how do we use diagnostic
criteria? Here again these criteria are indeed useful to
compare populations but, even updated, they have limi-
tations at the level of an individual patient. As a conse-
quence of their (too) strict use, the associated risk is
then the delay needed to fulfill enough of those criteria
so that the diagnosis can be made.Early and late rheumatoid arthritis: two different
stories
Clinical experience clearly shows that acting early is the
best way to control disease and induce remission. Fur-
thermore, the combination of disease-modifying anti-
rheumatic drugs is more effective including anti-TNF
and methotrexate (MTX) at all stages of RA in patients
in whom low disease activity is not achieved on mono-
therapy with MTX. The ‘treat to target’ strategy for opti-
mal control of disease has been an important advance in
RA care.
Emery [3] rightly advocates that with RA we are al-
ways far too late and too often miss induction of remis-
sion. Although it makes sense to act early, we now
better understand the underlying mechanisms. At an
early stage, control of inflammation has been shown to
be very effective. This is the stage at which the disease is
driven by the classic RA lesion with migration of inflam-
matory cells from blood leading to ectopic lymphoid ac-
cumulation in the synovium, looking like an activated
lymph node. Of interest also is the fact that the bone
marrow of juxta-articular bone shows the same pattern,
at the site of bone edema [4]. Thus the question is: is
the process coming from the synovium then attacking
bone, or is it the other way around? Emery proposes the
use of the most effective drugs alone or even more in
combination at this stage to prevent or reduce the risk
of moving to the stage of chronic RA.
This group of patients with chronic RA consists of
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one TNF inhibitor. Disease has been present for many
years and destruction is obvious. This situation is typical
of another lost battle. Once again it can be predicted
that many of these patients will not respond to immune-
mediated therapies, because the disease is not driven by
TNF, interleukin-6, T cells, or B cells anymore (or has
never been driven) by these pathways. Even in the re-
sponders, chronicity is unfortunately still there, as easily
shown by relapse when stopping or even just reducing
treatment [5]. Treatment is as chronic as the disease.
Worse, over time, different pathways are now activated
because of prolonged inhibition of treatment-targeted
ones. Thus, blocking the TNF pathway can lead to acti-
vation of the T helper 17 (Th17) pathway in patients los-
ing response [6]. Lack of response could result first from
the low expression of the target. It makes sense that pa-
tients responding to TNF should have a TNF-driven dis-
ease. Detection of functional TNF in those patients is in
line with this hypothesis [7]. Lack of enough specificity
could also contribute to a mixed response. Nistala and
Mauri [8] indicate that the use of an anti-CD20 antibody
by depleting all CD20-positive B cells can also eliminate
the beneficial regulatory B cells.
Mesenchymal cells: the forgotten target
Not only does chronic synovium infiltrate lead to the in-
flammatory clinical picture but its chronicity induces
changes in resident cells, namely mesenchymal cells
such as synoviocytes in the synovium but also in lymph
nodes and bone marrow. When such damage has oc-
curred, increased survival of these modified cells will
now induce a self-perpetuating disease in the absence of
the initial inflammation.
Epigenetic studies on mesenchymal cells, specifically
synoviocytes, have clearly indicated that cells from the
RA joint are different from cells from normal and osteo-
arthritis synovium [9]. Frank-Bertoncelj and Gay [10] ad-
vocate, and have been advocating for years, that acting
at this late stage on inflammation and immune targets is
useless. Instead, the modified synoviocytes should be the
target. Years ago, this was done with radioactive or sur-
gical synovectomy in a non-specific manner. Today new
strategies need to be developed to target those cells
through metabolic intervention, as in cancer, or their
physical elimination or both. One limitation is to find
ways to target specifically those cells known to lack
markers.
To further support the concept of early intervention, it
is possible that such changes in mesenchymal cells occur
rather quickly. At least in vitro, exposure of synoviocytes
to a combination of proinflammatory cytokines for a few
days is enough to induce such changes, making these
cells less sensitive to apoptotic signals.The pre-clinical phase, prevention, and eradication
Studies using samples collected years before the clinical
signs appear have indicated that normal individuals who
will, or at least could, develop RA show signs of immune
activity years before. Appearance of autoantibodies and in-
creased levels of proinflammatory cytokines have been de-
scribed [11]. These abnormalities become more common
when the disease is ready to start. However, the rate of RA
is too low to justify detection of these markers even in a
selected, otherwise healthy population.
Exogenous and endogenous inducers have been identi-
fied. Oral infection leads to parodontopathies. Porphyro-
monas gingivalis has been identified as an important
target because it can induce changes in proteins, making
them (auto)antigenic. However, again reflecting the het-
erogeneity, other mechanisms have been proposed, in-
cluding lung inflammation possibly through smoking
and changes in the bacterial microbiote. These later
changes in the intestinal microbiote are starting to be
identified, possibly leading to disease initiation through
changes in the T-cell phenotype toward a more inflam-
matory Th17 pathway [12].
Because of such a long list, it is difficult today to select a
simple way to prevent RA. However, this needs to be kept
in mind, as it will be the best way to eliminate the disease.
Large studies could demonstrate the influence of better
hygiene and more specifically if vaccination against a
pathogen could have an effect on RA incidence years later.
If the origin of RA is caused simply by a single infectious
agent, then the disease should disappear. Given the proven
association of cigarette smoking in the causation of RA via
induction of anti-cyclic citrullinated peptide in HLA-
susceptible individuals, cessation of smoking remains the
only plausible preventative strategy [13].
At the undifferentiated arthritis stage, the patients
complaining of arthralgias may have transient swelling,
but, when these patients are seen, joint examination is
usually normal. Current markers are not very useful.
This is where the first battle can be lost. There are two
options: do we wait and see, or do we act quickly? This
would imply treatment with drugs with a good safety ef-
ficacy balance. In that case, who should prescribe: the
primary care physician or the specialist? If the latter, we
would need more specialists with rapid access. At the
end, this is, and remains, a health-system decision. As
daily clinical practice indicates, acting at that stage is the
best way to prevent extension and to allow drug-free re-
mission. Maybe the risk is to treat some patients who
are not going to develop RA. However, the net benefit is
to avoid seeing patients at too late a stage.
Proposal for action
If RA is a series of lost battles, getting ready and having
the right protection are the way to go. Above all, the
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flammatory joint complaints. Having access early to
qualified care and treatment is, and will remain, the best
way to improve the outcome.
Modalities of the clinical trials have to be modified,
possibly transferring those used in cancer care, with
early combinations of drugs, followed by simplification
when remission is obtained to drug-free follow-up. Tar-
geting needs to be adjusted to the stage of the disease,
possibly using a combination regimen at the start. This
should include new targets beyond the classic immune-
related ones.
Better interaction between academia, the drug indus-
try, and health authorities should develop in order to
have better access to bio-collections and to results of tri-
als, specifically negative ones [14]. I do hope you will
enjoy reading this series of articles and that they will
stimulate new ideas for improvement.Note: This article is part of the collection ‘Why is there persistent
disease despite aggressive therapy of rheumatoid arthritis? ’, edited
by Pierre Miossec. Other articles in this series can be found at
http://arthritis-research.com/series/residualAbbreviations
HLA: Human leukocyte antigen; MTX: Methotrexate; RA: Rheumatoid arthritis;
Th17: T helper 17; TNF: Tumor necrosis factor.
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